BioPharma Dive

Pfizer drug acquired in Seagen deal disappoints in lung cancer study

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
Nasdaq

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion ...

ANKTIVA (nogapendekin alfa inbakicept) is our lead biologic product and a first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein. We are commercializing ANKTIVA for the treatment ...
PMLive

Candel Therapeutics appoints Mark Sims as Chief Commercial Officer

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective 6 July 2026. Sims is a seasoned oncology ...
Stocktwits on MSN

PFE stock continues to drop as lung cancer trial disappointment overshadows Ibrance win

Investors continue to be weighed down by the mixed results from a late-stage lung cancer trial earlier this week. ・Pfizer, on ...
Morningstar

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer Commercial availability achieved within two months of announcing MENA ...

Jazz Pharmaceuticals' lung cancer drug setback in late-stage trials: Here's why the stock impact may be more limited than it looks

The long-term thesis remains largely unchanged.